Have the new drugs relieved the burden of the orthopedic surgeon?

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 214-218

  Pap, Géza ^a   Shigeyama, Yukio ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Mizushima Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; HUMAN; JOINT DESTRUCTION; ORTHOPEDIC SURGERY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; ORTHOPEDIC PROCEDURES;

EID: 0035005187     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00011     Document Type: Review

References (60)

1. 1 Gschwend N: The rheumatic hand. Orthopade 1998, 27:167-174.
2. 2 Tillmann K: Synovectomy in treatment of inflammatory rheumatic diseases: historical or current? Z Orthop Ihre Grenzgeb 1991, 129:129-135.
3. 3 Klug S, Wittmann G, Weseloh G: Arthroscopic synovectomy of the knee joint in early cases of rheumatoid arthritis: follow-up results of a multicenter study. Arthroscopy 2000, 16:262-287.
4. 4 Creighton MG, Callaghan JJ, Olejniczak JP, et al.: Total hip arthroplasty with cement in patients who have rheumatoid arthritis: a minimum ten-year follow-up study. J Bone Joint Surg Am 1998, 80:1439-1445.
5. 5 Chmell MJ, Scott RD: Total knee arthroplasty in patients with rheumatoid arthritis: an overview, Clin Orthop 1999, 366:54-60.
6. 6 Hargreaves D, Emery R: Total elbow replacement in the treatment of rheumatoid disease. Clin Orthop 1999, 366:61-71.
7. 7 Stanley JK: Soft tissue surgery in rheumatoid arthritis of the hand. Clin Orthop 1999, 366:78-90.
8. 8 Christensson D, Saveland H, Rydholm U: Cervical spine surgery in rheumatoid arthritis: a Swedish nation-wide registration of 83 patients. Scand J Rheumatol 2000, 29:314-319.
9. 9 Toolan BC, Hansen ST, Jr: Surgery of the rheumatoid foot and ankle. Curr Opin Rheumatol 1998, 10:116-119.
10. 10 Bogoch ER, Moran EL: Bone abnormalities in the surgical treatment of patients with rheumatoid arthritis. Clin Orthop 1999, 366:8-21.
11. 11 Pap T, Muller-Ladner U, Gay RE, et al.: Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000, 2:361-367. This article is a thorough review of the different roles of fibroblasts in the pathogenesis of RA.
12. 12 Justen HP, Pommer S, Leeb I, et al.: Long-term results of open knee synovectomy in later cases of rheumatoid arthritis. Z Rheumatol 1999, 58:201-206.
13. 13 Tillmann K: Value of synovectomy in surgical rheumatology [news]. Z Orthop Ihre Grenzgeb 2000, 13B:Oa17-Oa18.
14. 14 Ochi T, Iwase R, Kimura T, et al.: Effect of early synovectomy on the course of rheumatoid arthritis. J Rheumatol 1991, 18:1794-1798.
15. 13 Doets HC, Bierman BT, von Soesbergen RM: Synovectomy of the rheumatoid knee does not prevent deterioration: 7-year follow-up of 83 cases. Acta Orthop Scand 1989, 60:523-525.
16. 18 McEwen C: Multicenter evaluation of synovectomy in the treatment of rheumatoid arthritis: report of results at the end of five years. J Rheumatol 1988, 15:765-769.
17. 17 Goldring SR, Gravallese EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000, 12:195-199. The authors give new insights on the pathogenesis of bone erosions in RA and provide evidence that osteoclasts are regulated by novel factors, termed osteoclast differentiation factor and osteoprotegerin.
18. 18 Robertsson O, Knutson K, Lewold S, et al.: Knee arthroplasty in rheumatoid arthritis: a report from the Swedish Knee Arthroplasty Register on 4381 primary operations 1985-1995. Acta Orthop Scand 1997, 68:545-553.
19. 19 Pap T, Aicher WK, Sainsbury I, et al.: Activated fibroblasts from the interface membrane around loose joint arthroplasties resorb bone in the absence of osteoclasts [abstract]. Arthritis Rheum 1999, 42(suppl):S154.
20. 20 Pap T, Pap G, Hummel KM, et al.: Membrane type matrix metalloproteinase 1 (MT-MMP1) is abundantly expressed in fibroblasts and osteoclasts at the bone-implant interface of aseptically loosened joint arthroplasties in situ. J Rheumatol 1999, 26:166-169.
21. 21 Westacott CI, Taylor G, Atkins R, et al.: Interleukin 1 alpha and beta production by cells isolated from membranes around aseptically loose total joint replacements. Ann Rheum Dis 1992, 51;638-642.
22. 22 Shigeyama Y, Pap T, Pap G, et al.: In situ expression of osteoclast differentiation factor (ODF) in the synovial-like membrane (SLM) of aseptically loosened joint prostheses [abstract]. Arthritis Rheum 1999, 42(suppl):S284.
23. 23 Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602. This article represents an excellent study of the effects of the combination of infliximab and methotrexate in the treatment of RA and opens new perspectives for the use of these two drugs.
24. 24 Markham A, Lamb HM: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000, 59:1341-1359. This review article gives an extended summary of the present knowledge of the pharmacodynamic and pharmacokinetic properties of infliximab and its use in the treatment of RA.
25. 25 Maini RN: The role of cytokines in rheumatoid arthritis: the Croonian lecture 1995. J R Coll Physicians Lond 1996, 30:344-351.
26. 26 Pisetsky DS: Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med 2000, 342:810-811.
27. 27 Butler DM, Maini RN, Feldmann M, et al.: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995, 6:225-230.
28. 28 Forre O, Haugen M, Hassfeld WG: New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol 2000, 29:73-84. This extensive report gives an interesting review of recent knowledge of cartilage destruction in RA and of recent therapeutic strategies.
29. 29 Adorini L, Sinigaglia F: Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today 1997, 18:209-211.
30. 30 Moreland LW, Heck LW Jr, Koopman WJ: Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997, 40:397-409.
31. 31 Hauselmann HJ, Flechtenmacher J, Michal L, et al.: The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1995, 39:478-488.
32. 32 Strand V, Cohen S, Schiff M, et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999, 159:2542-2550.
33. 33 Smolen JS, Emery P: Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology (Oxford) 2000, 39(suppl)1:48-56.
34. 34 Emery P, Breedveld FC, Lemmel EM, et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
35. 33 Sharp JT, Strand V, Leung H, et al.: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000, 43:495-505. This paper compares the ability of leflunomide, methotrexate, and sulfasalazine to retard radiographic progression in RA and presents novel data on the effect of leflunomide to delay the progression of erosion and joint space narrowing in RA.
36. 36 Smolen JS: Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol 1999, 112(suppl):15-21
37. 37 Prakash A, Jarvis B: Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999, 58:1137-1184.
38. 38 Gay S, Muller-Ladner U, Hummel KM, et al.: Anticytokines, Osteoarthritis Cartilage 1999, 7:317-318.
39. 39 Gay S: Rheumatoid arthritis: editorial review. Curr Opin Rheumatol 2000, 12:179-180.
40. 40 Neidhart M, Gay RE, Gay S: Anti-Interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2000, 43:1719-1728.
41. 41 O'Dell JR: Anticytokine therapy: a new era in the treatment of rheumatoid arthritis? N Engl J Med 1999, 340:310-312.
42. 42 Gabay C, Arend WP: Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol 1998, 20:229-246.
43. 43 Gabay C: IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis. Expert Opin Invest Drugs 2000, 9:113-127. This paper gives a thorough review of the role of IL-1 in the pathogenesis of RA and of recent approaches to block its effects.
44. 44 Ulfgren AK, Andersson U, Engstrom M, et al.: Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000, 43:2391-2396.
45. 45 Elliott MJ, Maini RN, Feldmann M, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
46. 46 Jarvis B, Faulds D: Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999, 57:945-966.
47. 47 Omrust SV, Lamb HM: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998, 10:397-422.
48. 48 Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
49. 49 Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
50. 50 Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
51. 51 Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1 999, 340:253-259.
52. 52 Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etaner-cept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593. This article represents a particularly interesting comparison of etanercept and methotrexate in the treatment of patients with early rheumatoid arthritis and offers new perspectives for therapy in these patients.
53. 53 Bresnihan B: Treatment of rheumatoid arthritis with interleukin 1 receptor atagonist. Ann Rheum Dis 1999, 5S(suppl)1:l96-l98.
54. 54 Drevlow BE, Capezio J, Lovis R, et al.: Phase I study of recombinant human interleukin-1 receptor (rhu IL-1R) administered intra-articularly in active rheumatoid arthritis [abstract]. Arthritis Rheum 1993, 36:S39.
55. 55 Drevlow BE, Lovis R, Haag MA, et al.: Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995, 39:257-265.
56. 56 Jiang Y, Genant HK, Watt I, et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009. This is an interesting multicenter, double-blind, dose-ranging, randomized, placebo-controlled study showing that IL-1RA retards radiologic disease progression in patients with RA.
57. 57 Bresnihan B, Alvaro-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recambinant human interleukln-1 receptor antagonist. Arthritis Rheum 1998, 41:2136-2204.
58. 58 Shigeyama Y, Pap T, Kunzler P, et al.: Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000, 43:2523-2530.
59. 59 Kong YY, Feige U, Sarosi I, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
60. 60 Pap T, Muller-Ladner U, Gay RE, Gay S: Gene therapy in rheumatoid arthritis: how to target joint destruction? Arthritis Res 1999, 1:5-9.